Study identifier:M/34273/40
ClinicalTrials.gov identifier:NCT01471171
EudraCT identifier:N/A
CTIS identifier:N/A
A multiple dose, randomised, double-blind, placebo controlled, 2 period crossover clinical trial to assess the effect of aclidinium bromide 400 μg BID on exercise endurance in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD)
Phase 3
No
Aclidinium Bromide, Placebo
All
112
Interventional
40 Years +
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Oct 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Aclidinium bromide 3-week treatment periods | Drug: Aclidinium Bromide 1 puff of 400 micro grams in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h) |
Experimental: Placebo 3-week treatment periods | Drug: Placebo 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) |